CRISPR-Cas9 technology was utilized to generate SOX2-KO cells from glioma cell lines (U251, LN229, and CCF) and primary GSCs, which exhibit relatively higher SOX2 expression and possess higher HCMV infection efficiency than the other three cell lines. The gene discussed is SOX2; the disease is central nervous system cancer.